Author Correction: A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas

Leandro C Cerchietti^#^{1

2}, Eloisi C Lopes^#³, Shao Ning Yang¹, Katerina Hatzi^{1

2}, Karen L Bunting^{1

2}, Lucas A Tsikitas¹, Alka Mallik¹, Ana I Robles⁴, Jennifer Walling⁵, Lyuba Varticovski⁴, Rita Shaknovich⁶, Kapil N Bhalla⁷, Gabriela Chiosis⁸, Ari Melnick^{9

10}

Affiliations

¹ Division of Hematology and Oncology, Weill Cornell Medical College of Cornell University, New York, New York, USA.
² Department of Pharmacology, Weill Cornell Medical College of Cornell University, New York, New York, USA.
³ Department of Molecular Pharmacology and Chemistry, Sloan-Kettering Institute, New York, New York, USA.
⁴ Laboratory of Human Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
⁵ Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
⁶ Department of Pathology, Weill Cornell Medical College of Cornell University, New York, New York, USA.
⁷ Medical College of Georgia Cancer Center, Augusta, Georgia, USA.
⁸ Department of Molecular Pharmacology and Chemistry, Sloan-Kettering Institute, New York, New York, USA. chiosisg@mskcc.org.
⁹ Division of Hematology and Oncology, Weill Cornell Medical College of Cornell University, New York, New York, USA. amm2014@med.cornell.edu.
¹⁰ Department of Pharmacology, Weill Cornell Medical College of Cornell University, New York, New York, USA. amm2014@med.cornell.edu.

^# Contributed equally.

Published Erratum

Leandro C Cerchietti et al. Nat Med. 2024 May.

. 2024 May;30(5):1503.

doi: 10.1038/s41591-024-02957-0.

¹ Division of Hematology and Oncology, Weill Cornell Medical College of Cornell University, New York, New York, USA.
² Department of Pharmacology, Weill Cornell Medical College of Cornell University, New York, New York, USA.
³ Department of Molecular Pharmacology and Chemistry, Sloan-Kettering Institute, New York, New York, USA.
⁴ Laboratory of Human Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
⁵ Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
⁶ Department of Pathology, Weill Cornell Medical College of Cornell University, New York, New York, USA.
⁷ Medical College of Georgia Cancer Center, Augusta, Georgia, USA.
⁸ Department of Molecular Pharmacology and Chemistry, Sloan-Kettering Institute, New York, New York, USA. chiosisg@mskcc.org.
⁹ Division of Hematology and Oncology, Weill Cornell Medical College of Cornell University, New York, New York, USA. amm2014@med.cornell.edu.
¹⁰ Department of Pharmacology, Weill Cornell Medical College of Cornell University, New York, New York, USA. amm2014@med.cornell.edu.

^# Contributed equally.

No abstract available

Erratum for

A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas.
Cerchietti LC, Lopes EC, Yang SN, Hatzi K, Bunting KL, Tsikitas LA, Mallik A, Robles AI, Walling J, Varticovski L, Shaknovich R, Bhalla KN, Chiosis G, Melnick A. Cerchietti LC, et al. Nat Med. 2009 Dec;15(12):1369-76. doi: 10.1038/nm.2059. Epub 2009 Nov 22. Nat Med. 2009. PMID: 19966776 Free PMC article.